Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Clin Cancer Res. 2015 Mar 25;21(21):4947–4959. doi: 10.1158/1078-0432.CCR-14-2955

Figure 6. CDK4/6 inhibition antagonizes fusion-positive RMS tumor growth in vivo.

Figure 6

Mice were injected intramuscularly with Rh30 or Rh28 cells. After formation of a palpable tumor, mice were randomized to receive vehicle (n=10) or 200 mg/kg LEE011 (n=10) daily by oral gavage for 21 days. A, LEE011 diminishes phosphorylation of RB in xenograft tumors derived from Rh30 and Rh28 cells. Intensity ratios of phospho-RB to RB are normalized to the ratio in vehicle-treated mouse #1. LEE011 abrogates tumor progression in (B) Rh28-derived and (C) Rh30-derived xenograft models.